Philip Procter, CEO of GPBio & Co-founder of Biomimetic Innovations, shares the OsStic journey of discovery and its path to commercialization in an interview with SmartTRAK

Philip Procter started on a quest several decades ago to solve trauma hardware failure in patients through the development of an adhesive solution. The journey began in earnest after a UK meeting with craniomaxillofacial surgeons facing difficult problems they felt could only be solved with an adhesive technology in combination with implants. Procter was convinced early on that the adhesive solution would have to come from nature studying everything from gecko-based technology to sticky frogs in Australia to Mytilus edulis (common mussel) food protein. But it was after demonstrating the potential of a prototype glue in Sweden in 2014 that his journey led him to become a faculty member of the University of Uppsala, Sweden, and he and his partner Dr Gerard Insley working together with Professor Håkan Engqvist and a team of students developed the technology that is known today as OsStic^: a technology with the potential to join implant to bone, bone to bone, soft tissue to bone, and soft tissue to soft tissue.

GPBio and PBC Biomed, both Irish-based companies, joined forces in 2020 to develop and commercialize the OsStic bone adhesive technology through the formation of a new company, Biomimetic Innovations Ltd. Company CEO Philip Procter shared more about the OsStic technology, how it came about and next steps for bringing the product to market in an interview with SmartTRAK’s Lisa Mahan. To find out more about the Company and its operation, click on the following video to listen to the interview, recorded via Uberconference. (17:49 min) A link to download a complete transcript of the interview is also provided below.

Robotics continued to help fuel growth in orthopedics in Q221 as new products and companies heat up the market and enabling technologies gain momentum across TJR.

Once again, robotics contributed to revenue growth in the orthopedics market in Q221 and competition continues to heat up with several regulatory clearances and other developments from new market entrants in the quarter. Aside from robotics, enabling technology including intra-operative augmented reality, preoperative planning and navigation reached a number of milestones in Q221 across all indications in total joint replacement.

Among the many topics, including company revenues, market shares, charts and expert analysis, covered in the comprehensive Q221 CAS Ortho Market Recap* are:

Pete Wehrly, CEO of VIVEX Biologics, discusses the Company and its diverse portfolio in orthopedics and wound care in an interview with SmartTRAK

In an interview with SmartTRAK, VIVEX Biologics’ CEO Pete Wehrly discusses how VIVEX’ diverse portfolio of regenerative solutions in orthopedics and wound care can potentially turn the regenerative medicine industry on its ear with an eye towards proving, through economic and clinical evidence, that its technologies are better than anything on the market today.

To find out more about the Company, its technologies and what’s next in terms of clinical research and reimbursement, click on the following video to see the interview recorded live at the North American Spine Society (NASS) Annual Meeting held in Boston Sept 29 to Oct 2, 2021 (11:24 min). A link to download the complete transcript of the interview is also provided below.

New product introductions and innovative technologies set the stage for AOFAS 2021.

At the American Orthopaedic Foot & Ankle Society (AOFAS) meeting in Charlotte, NC, SmartTRAK identified several key themes and takeaways from the meeting as manufacturers showcased innovation through new product introductions, continue to focus on hallux valgus corrections and the associated instrumentation allowing for reproducible outcomes and the advancements of 3D printed solutions.

The Luster of New Products Help Drive Healthy Foot & Ankle Competition

The foot & ankle space does not look like it is slowing down anytime soon based on the products highlighted at AOFAS. Innovation is helping to drive growth in the US market for Foot & Ankle Repair and Reconstruction, which is projected to reach a 5-year CAGR of +4.9% according to SmartTRAK’s Foot & Ankle Market Overview. Newsworthy highlights include:

This Year’s AAOS Annual Meeting was no different--scientific bodies are still divided on the efficacy of HA therapy and it remains a “bête noire” sitting outside of the gold standard for the treatment of patients affected by knee OA.

For some time now, hyaluronic acid (HA) viscosupplement injections (aka intra-articular (IA) HA injections) have become a standard and an integral part of the physician’s armamentarium in the treatment continuum for an ever-growing number of patients suffering from knee osteoarthritis (OA). With OA universally established as the most prevalent form of arthritis afflicting the US population, SmartTRAK estimates that approximately 2.3 million HA injection procedures will be performed for knee OA alone.  Yet, confusion and debates persist over the efficacy of HA therapy, product composition and source of the HA, volume and number of injections, treatment cost and, more recently, regulatory classification for HA products. SmartTRAK believes that the plethora of studies on the use of HA injection that show varied results is ...

To download and read the complete article by Freddy Buntoum, Sr. Analyst, Orthobiologics and Regenerative Medicine at SmartTRAK, please click the button below.

The US Spine market appears to be continuing on a skyward trajectory...but what’s really on the horizon for Spine?

With Q221 year-over-year growth up almost 46%, the US Spine market appears to be continuing on a skyward trajectory. However, as compared to Q219, Q221 saw growth of only +1.3%, reflecting ongoing COVID challenges. What’s really on the horizon for Spine? While the first half of 2021 has certainly looked much brighter than 2020, one big question remains: how big of an impact will the Delta variant surge have on the back half of the year?

Among the many topics covered in detail in our comprehensive Q221 Spine Market Recap* are:

Soft Tissue Fixation Continues to Pick Up Steam in Q2 2021

With the world trying to move past the negative impacts of COVID-19, the Soft Tissue Fixation market continued to make significant advancements in the second quarter of 2021. The quarter saw a continued rise in case volumes for elective sports medicine procedures worldwide driven primarily through market recovery in the wake of the COVID-19 pandemic. 

Among the many topics covered in detail in our comprehensive Q221 Soft Tissue Fixation Market Recap* are:

The SmartTRAK team is excited to head to Boston for the North American Spine Society (NASS) meeting. Need better business intelligence? Visit us at Booth 3719. SmartTRAK is the most comprehensive business intelligence platform for the MedTech industry. SmartTRAK's real-time data allows everyone in your organization to tap into the same data to drive strategic consistency and increase collaboration across your enterprise. Watch the video below to learn how SmartTRAK can help.

Planning to go to NASS? SmartTRAK will be represented in Boston by:

• Julianne Burns, GM, Spine
• Elise Wolf, VP & GM, Orthopedics
• Kristina Meyer, CCO
• Matt Golembeski, Dir. of Sales
• Joe Mish, Dir. of Sales
• Tim Patrick, Sr. Manager of Corporate Accounts

Meet with us in Boston to learn more about what's coming down the road, including:

• Integration: Combine our data with yours and integrate it into your data analytic platform.
• Customization: Tailor SmartTRAK to match your company's business and create your own business intelligence solution.
• Expanded Functionality: Drive strategic consistency across your enterprise with user-specific enhancements and increase collaboration across your team

Schedule a meeting today!
We know you're going to love what's coming down the road!

Trauma market rebounds as top segments drive growth amid easy YoY comps

The Trauma Market experienced another quarter of healthy growth as the WW and US Trauma Markets ended Q221 up YoY compared to Q220.  Looking forward to Q321, SmartTRAK feels that trauma procedures will likely not be as heavily impacted by the rise in the Delta variant as its elective procedure counterparts. We will continue to monitor the situation as the variant impacts states, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 Trauma Market Recap* are:

At AAOS 2021, outgoing President Joseph Bosco III, MD, shares the positive changes in orthopedics accelerated by COVID-19 from the move of procedures to ASCs to increased use of technology

Joseph Bosco III, MD, vice-chair of clinical affairs for NYU Langone Orthopedics and outgoing president of the American Academy of Orthopedic Surgeons (AAOS) presided over the Academy during a transformative time accelerated by COVID-19. Dr. Bosco began his presidency in March 2020 just as the pandemic shut down many areas of the US impacting the healthcare system and orthopedic procedures. As Dr. Bosco prepared to turn over the reins at AAOS 2021, he spoke with SmartTRAK about his experience during the year and how the pandemic and technology are creating opportunities and accelerating trends that will change the practice of orthopedics for years to come.

To find out more, click on the following video. A link to download a complete transcript of the interview is also available below.

SmartTRAK: Lisa Mahan here with Smart Track. Today, I have the honor to be talking to Dr. Joseph Bosco, III, outgoing president of the American Academy of Orthopedic Surgeons. Dr. Bosco, thank you for talking to me today.

Dr. Joseph Bosco: Well, thank you for having me.

Ending your term as president of AAOS must be a bit bittersweet. You've served during a challenging time with the disruption from COVID. How was it navigating through the pandemic?